Related Experiment Video
Updated: Jul 6, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
The evaluation and management of cardiogenic shock
1University of Vermont College of Medicine, Burlington, Vermont 05401, USA. prospero.gogo@vtmednet.org
Insights
Cardiogenic shock (CS) following acute myocardial infarction (AMI) has high mortality. Early revascularization and supportive therapies are key, with newer treatments targeting inflammation and cardiovascular support.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) is the primary cause of mortality in acute myocardial infarction (AMI) patients.
- High mortality rates (40-60% at 1 month) persist for CS complicating AMI.
- Inflammation plays a role in CS pathogenesis, beyond pump failure.
Purpose of the Study:
- To outline the institutional critical pathway for managing CS post-AMI.
- To highlight current and emerging therapeutic strategies for CS.
Main Methods:
- Review of current treatment protocols for CS in AMI.
- Integration of established and novel therapeutic approaches.
Main Results:
- Dominant therapy involves early mechanical revascularization (PCI or CABG).
- Supportive measures include vasopressors and intra-aortic balloon pump.
- Emerging therapies focus on anti-inflammatory actions and cardiovascular support.
Conclusions:
- A multi-faceted approach is crucial for managing CS post-AMI.
- Timely revascularization combined with supportive and novel therapies improves outcomes.
- Ongoing research targets inflammation and cardiovascular support for better patient recovery.
Abstract:
Cardiogenic shock (CS) continues to be the leading cause of death in patients who present to the hospital with acute myocardial infarction (AMI). Mortality in patients with AMI complicated by CS remains extremely high, with 1-month mortality rates ranging from 40% to 60%. Although pump failure is the dominant etiologic feature of CS after AMI, the inflammatory system has been implicated in its pathogenesis. The dominant therapy for treatment of CS is early mechanical revascularization with either percutaneous coronary intervention or coronary artery bypass graft surgery. Supportive measures such as intravenous vasopressors or intra-aortic balloon counterpulsation can complement the benefit of definitive revascularization. Newer therapies are directed at mitigating the inflammatory response or supporting cardiovascular function until either patient recovery or until other destination therapy is available. The strategies in this critical pathway outline the general approach in treating CS after AMI at our institution.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Pericarditis IV: Nursing Management
